Abstract
Background: The prevalence of pituitary tumors (PT) has been estimated from 15 % of all brain tumors. Both physiologic and psychologic functions can be disturbed, affecting the individual's life functions and quality(Qol). PT are classified by size and hormonal productivity: Macroadenomas (MA) > 1cm and microadenomas (mA) < 1cm tumors; those producing excess hormonal secretions as functional adenomas (FA) and those with normal hormonal function as non-functional adenomas (NFA). Hormonal deficiencies can occur in association with all PTs. Patient complaints of cognitive dysfunction and QoL changes have been validated to occur in patients with hormonally active tumors, but not for patients with microadenomas and non-functional tumors.
Purpose: To determine if cognitive deficits are perceived by patients with NFmA when compared to patients with NFMA.
Methods: Cognitive function was evaluated using a modified, disease specific version of the FACT-Cog questionnaire, limited to perception of cognitive capacity. Perceived ability to learn and concentrate, distractibility, mental agility, factual and short term memory and verbal recall were evaluated and scored on a 6 point Likert scale from none to very much dysfunction.
Results: 28 pre treatment patients enrolled, 14 in each group (8F/6M). Neither group reported co-morbidities, and pituitary deficiencies were similar and the mean age in mA group was younger (37 vs 51years). 26 patients reported experiencing one or more cognitive dysfunction(s). There was a significantly greater perception of cognitive function for patients with NFmA (M=3.3, SD=1.13) than NFMA (M=2.6, SD=6.1) t (27)=2.33, p = 0.027). This was consistent for all parameters except memory, which was perceived as equally problematic.
Conclusion: Patients with PTs perceive cognitive dysfunction regardless of the size of tumor. Further evaluation is warranted to determine if this translates to performance deficits. Likewise, the etiology of cognitive deficits requires further elucidation.
Sigma Membership
Non-member
Type
Presentation
Format Type
Text-based Document
Study Design/Type
N/A
Research Approach
N/A
Keywords:
Cognitive Assessment, Non-Functional, Pituitary Adenomas
Recommended Citation
Yedinak, Christine G., "Pituitary tumors: Patient perceptions of cognitive deficits" (2012). INRC (Congress). 117.
https://www.sigmarepository.org/inrc/2012/presentations_2012/117
Conference Name
23rd International Nursing Research Congress
Conference Host
Sigma Theta Tau International
Conference Location
Brisbane, Australia
Conference Year
2012
Rights Holder
All rights reserved by the author(s) and/or publisher(s) listed in this item record unless relinquished in whole or part by a rights notation or a Creative Commons License present in this item record.
All permission requests should be directed accordingly and not to the Sigma Repository.
All submitting authors or publishers have affirmed that when using material in their work where they do not own copyright, they have obtained permission of the copyright holder prior to submission and the rights holder has been acknowledged as necessary.
Acquisition
Proxy-submission
Pituitary tumors: Patient perceptions of cognitive deficits
Brisbane, Australia
Background: The prevalence of pituitary tumors (PT) has been estimated from 15 % of all brain tumors. Both physiologic and psychologic functions can be disturbed, affecting the individual's life functions and quality(Qol). PT are classified by size and hormonal productivity: Macroadenomas (MA) > 1cm and microadenomas (mA) < 1cm tumors; those producing excess hormonal secretions as functional adenomas (FA) and those with normal hormonal function as non-functional adenomas (NFA). Hormonal deficiencies can occur in association with all PTs. Patient complaints of cognitive dysfunction and QoL changes have been validated to occur in patients with hormonally active tumors, but not for patients with microadenomas and non-functional tumors.
Purpose: To determine if cognitive deficits are perceived by patients with NFmA when compared to patients with NFMA.
Methods: Cognitive function was evaluated using a modified, disease specific version of the FACT-Cog questionnaire, limited to perception of cognitive capacity. Perceived ability to learn and concentrate, distractibility, mental agility, factual and short term memory and verbal recall were evaluated and scored on a 6 point Likert scale from none to very much dysfunction.
Results: 28 pre treatment patients enrolled, 14 in each group (8F/6M). Neither group reported co-morbidities, and pituitary deficiencies were similar and the mean age in mA group was younger (37 vs 51years). 26 patients reported experiencing one or more cognitive dysfunction(s). There was a significantly greater perception of cognitive function for patients with NFmA (M=3.3, SD=1.13) than NFMA (M=2.6, SD=6.1) t (27)=2.33, p = 0.027). This was consistent for all parameters except memory, which was perceived as equally problematic.
Conclusion: Patients with PTs perceive cognitive dysfunction regardless of the size of tumor. Further evaluation is warranted to determine if this translates to performance deficits. Likewise, the etiology of cognitive deficits requires further elucidation.